Recent Advances in Antibody Therapeutics
Since first receiving approval in 1986, antibody-based therapeutics have been the most successful modality for the treatment of various diseases. This Special Issue of IJMS, "Recent Advances in Antibody Therapeutics", presents leading-edge articles and reviews for discovery, development, a...
Saved in:
| Other Authors: | |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_87408 | ||
| 005 | 20220706 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20220706s2022 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-0365-4354-3 | ||
| 020 | |a 9783036543536 | ||
| 020 | |a 9783036543543 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-0365-4354-3 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a GP |2 bicssc | |
| 072 | 7 | |a PN |2 bicssc | |
| 100 | 1 | |a Heo, Yong-Seok |4 edt | |
| 700 | 1 | |a Heo, Yong-Seok |4 oth | |
| 245 | 1 | 0 | |a Recent Advances in Antibody Therapeutics |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2022 | ||
| 300 | |a 1 electronic resource (238 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a Since first receiving approval in 1986, antibody-based therapeutics have been the most successful modality for the treatment of various diseases. This Special Issue of IJMS, "Recent Advances in Antibody Therapeutics", presents leading-edge articles and reviews for discovery, development, and clinical applications of therapeutic antibodies, covering antibody drug conjugates (ADCs), GPCR-targeting antibodies, a functional antibody screening, bioassay of bispecific antibodies, antibody applications for cardiovascular diseases, antibody delivery to CNS, etc. The excellent studies in this Special Issue would valuable insight for scientists and clinicians in the field of therapeutic antibodies | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Research & information: general |2 bicssc | |
| 650 | 7 | |a Chemistry |2 bicssc | |
| 653 | |a interleukin 33 | ||
| 653 | |a ST2 receptor | ||
| 653 | |a scFv | ||
| 653 | |a C2_2E12 | ||
| 653 | |a bladder cancer | ||
| 653 | |a antibodies | ||
| 653 | |a immune checkpoint inhibitors | ||
| 653 | |a antibody-drug conjugates | ||
| 653 | |a sacituzumab govitecan | ||
| 653 | |a enfortumab vedotin | ||
| 653 | |a erdafitinib | ||
| 653 | |a cost-effectiveness | ||
| 653 | |a G protein-coupled receptor | ||
| 653 | |a membrane protein | ||
| 653 | |a antigen | ||
| 653 | |a therapeutic antibody | ||
| 653 | |a anti-angiogenesis | ||
| 653 | |a delta-like ligand | ||
| 653 | |a irinotecan | ||
| 653 | |a paclitaxel | ||
| 653 | |a VEGF | ||
| 653 | |a SARS-CoV-2 | ||
| 653 | |a spike protein | ||
| 653 | |a receptor-binding domain | ||
| 653 | |a phage display | ||
| 653 | |a monoclonal antibody | ||
| 653 | |a cytomegalovirus | ||
| 653 | |a peptide/major histocompatibility complex class I complex | ||
| 653 | |a T-cell-receptor-like antibody | ||
| 653 | |a affinity maturation | ||
| 653 | |a yeast surface display | ||
| 653 | |a combinatorial antibody library | ||
| 653 | |a agonist antibody | ||
| 653 | |a cell fate | ||
| 653 | |a bispecific antibodies | ||
| 653 | |a bioassays | ||
| 653 | |a mechanisms of action | ||
| 653 | |a binding assays | ||
| 653 | |a potency assays | ||
| 653 | |a atherosclerosis | ||
| 653 | |a inflammation | ||
| 653 | |a antibody therapy | ||
| 653 | |a blood-brain barrier | ||
| 653 | |a antibody | ||
| 653 | |a pharmacokinetics | ||
| 653 | |a disposition | ||
| 653 | |a biochemical and physicochemical properties | ||
| 653 | |a Fc binding | ||
| 653 | |a receptor-mediated transcytosis | ||
| 653 | |a brain shuttle | ||
| 653 | |a molecular Trojan horse | ||
| 653 | |a transferrin | ||
| 653 | |a anti-cancer antibody | ||
| 653 | |a antibody engineering | ||
| 653 | |a biophysical properties | ||
| 653 | |a computational methods | ||
| 653 | |a research cell bank | ||
| 653 | |a antibody therapeutics | ||
| 653 | |a recombinant antibodies | ||
| 653 | |a intracellular antibodies | ||
| 653 | |a single-chain antibody fragment | ||
| 653 | |a nanobody | ||
| 653 | |a Human papillomaviruses | ||
| 653 | |a HPV oncoproteins | ||
| 653 | |a HPV-associated cancer | ||
| 653 | |a HPV cancer therapy | ||
| 653 | |a asthma | ||
| 653 | |a refractory asthma | ||
| 653 | |a biomarker | ||
| 653 | |a n/a | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/5595 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/87408 |7 0 |z DOAB: description of the publication |